Lilly Diabetes and Walgreens launch diabetes hypoglycemia awareness campaign
16 April 2012 | By Eli Lilly and Company
Lilly Diabetes & Walgreens to help combat the problem of hypoglycemia unawareness...
List view / Grid view
News
Nascent and Catalent sign cancer antibody development deal
16 April 2012 | By Catalent Pharma Solutions
Nascent and Catalent announced the signing of a product development agreement...
Owen Mumford opens office in Shanghai
16 April 2012 | By Karen Taylor PR
Owen Mumford, one of the UK’s largest manufacturers of medical devices has opened its doors for business in China...
Rapid Micro Biosystems announces the 2013 availability of Growth Direct™ Systems
New applications improve the efficiency of microbial quality control processes...
Exclusive worldwide agreement to develop and commercialize Phase III cancer candidate vintafolide (EC145)
16 April 2012 | By Merck
Vintafolide is currently being evaluated in a Phase III clinical trial...
HORIBA Scientific offers KnowItAll® software for Raman spectral searching
13 April 2012 | By HORIBA Scientific
Bio-Rad’s KnowItAll® Informatics System software offered for use with the HORIBA Scientific range of Raman spectrometers...
Register and submit your abstract now to Label-free technologies!
13 April 2012 | By HORIBA Scientific
HORIBA Scientific, is proud to announce the organization of a label-free conference, in cooperation with ELSEVIER...
Oral lipid-based drug delivery solutions to meet complex bioavailability challenges presented by two global Catalent experts at AAPS workshop
12 April 2012 | By Catalent Pharma Solutions
Dr. Browne & Mr. Meissonnier will present...
Lonza and Agennix sign development and manufacturing deal for production of talactoferrin
Lonza and Agennix AG announced today an agreement for the production of Agennix’s first-in-class oral Dendritic Cell Mediated Immunotherapy (DCMI), talactoferrin, currently in Phase III testing for the treatment of non-small cell lung cancer (NSCLC).
BASF introduces extended solubilization and dermatology excipients portfolios
12 April 2012 | By BASF
After acquiring Cognis in 2011, BASF has significantly expanded its range of solubilization and dermatology excipients...
GSK provides update on corporate responsibility commitments in 2011 report
11 April 2012 | By GlaxoSmithKline
GlaxoSmithKline has published its Corporate Responsibility Report...
Catalent expert invited to share formulation development expertise at Aerosol School
11 April 2012 | By Catalent Pharma Solutions
Dr. Lei Mao, Project Director and Group Leader, R&D of Catalent Pharma Solutions to present...
Abbott’s HUMIRA® (adalimumab) approved in Europe for treatment of ulcerative colitis (UC)
11 April 2012 | By
The European Commission has approved HUMIRA®...
Corning to acquire majority of BD Discovery Labware
Corning Incorporated (NYSE: GLW) announced today that it has reached a definitive agreement with BD (Becton, Dickinson and Company) (NYSE:BDX) to acquire the majority of its Discovery Labware unit for approximately $730 million in cash. The acquisition is expected to be completed later this year, subject to customary closing conditions,…
Around the World in 80 ways – Catalent expert to present on clinical distribution supply chain at 2012 ISPE Japan
10 April 2012 | By Catalent Pharma Solutions
Esther Sadler-Williams will lead two discussions...
